Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma

Lenalidomide (LEN) maintenance (MT) post autologous stem cell transplantation (ASCT) is standard of care in newly diagnosed multiple myeloma (MM) but has not been compared to other agents in clinical trials. We retrospectively compared bortezomib (BTZ; n = 138) or LEN (n = 183) MT from two subsequen...

Descripción completa

Detalles Bibliográficos
Autores principales: Baertsch, Marc-Andrea, Mai, Elias K., Hielscher, Thomas, Bertsch, Uta, Salwender, Hans J., Munder, Markus, Fuhrmann, Stephan, Dührsen, Ulrich, Brossart, Peter, Neben, Kai, Schlenzka, Jana, Kunz, Christina, Raab, Marc S., Hillengaß, Jens, Jauch, Anna, Seckinger, Anja, Hose, Dirk, Luntz, Steffen, Sonneveld, Pieter, Lokhorst, Henk, Martin, Hans, Goerner, Martin, Hoffmann, Martin, Lindemann, Hans-Walter, Bernhard, Helga, Blau, Igor W., Scheid, Christof, Besemer, Britta, Weisel, Katja C., Hänel, Mathias, Dürig, Jan, Goldschmidt, Hartmut
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791127/
https://www.ncbi.nlm.nih.gov/pubmed/33414374
http://dx.doi.org/10.1038/s41408-020-00390-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791127/
https://www.ncbi.nlm.nih.gov/pubmed/33414374
http://dx.doi.org/10.1038/s41408-020-00390-3

Ejemplares similares